Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer.
Bepler G, Dilling TJ, Wagner H, Hazelton T, Williams C, Chen DT, Greenberg H, Walsh F, Simon G, Tanvetyanon T, Chiappori A, Haura E, Stevens C. Bepler G, et al. Among authors: williams c. J Thorac Oncol. 2011 Mar;6(3):553-8. doi: 10.1097/JTO.0b013e31820b8d88. J Thorac Oncol. 2011. PMID: 21289520 Free PMC article. Clinical Trial.
Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM, Bepler G. Chiappori AA, et al. Among authors: williams c. Clin Cancer Res. 2008 Mar 1;14(5):1464-9. doi: 10.1158/1078-0432.CCR-07-1508. Clin Cancer Res. 2008. PMID: 18316570 Clinical Trial.
Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer.
Bepler G, Sommers KE, Cantor A, Li X, Sharma A, Williams C, Chiappori A, Haura E, Antonia S, Tanvetyanon T, Simon G, Obasaju C, Robinson LA. Bepler G, et al. Among authors: williams c. J Thorac Oncol. 2008 Oct;3(10):1112-8. doi: 10.1097/JTO.0b013e3181874936. J Thorac Oncol. 2008. PMID: 18827606 Free PMC article. Clinical Trial.
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.
Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G. Haura EB, et al. Among authors: williams c. J Clin Oncol. 2010 Mar 10;28(8):1387-94. doi: 10.1200/JCO.2009.25.4029. Epub 2010 Feb 8. J Clin Oncol. 2010. PMID: 20142592 Free PMC article. Clinical Trial.
Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.
Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR. Bepler G, et al. Among authors: williams c. J Clin Oncol. 2013 Jul 1;31(19):2404-12. doi: 10.1200/JCO.2012.46.9783. Epub 2013 May 20. J Clin Oncol. 2013. PMID: 23690416 Free PMC article. Clinical Trial.
Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer.
Dilling TJ, Extermann M, Kim J, Thompson LM, Yue B, Stevens CW, Antonia S, Gray J, Williams C, Haura E, Pinder-Schenck M, Tanvetyanon T, Kim S, Chiappori A. Dilling TJ, et al. Among authors: williams c. Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):828-33. doi: 10.1016/j.ijrobp.2014.07.023. Epub 2014 Sep 9. Int J Radiat Oncol Biol Phys. 2014. PMID: 25216856 Clinical Trial.
11,148 results
You have reached the last available page of results. Please see the User Guide for more information.